ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0803

Rheumatoid Arthritis Practice Performance (RAPP) Project at 6 Years: Population Medicine (POPMED) Principles and Treat to Target (T2T) Care Yield Dramatic Improvements in Both Outcomes and Access for RA Patients and Productivity for Rheumatologists

William Arnold1, Erin Arnold1, David Sikes2, Gary Crump3, Kathleen Thomas4 and andrew johnson5, 1Arnold Arthritis and Rheumatology, Wilmette, IL, 2Florida Medical Clinic, Wesley Chapel, FL, 3Rheumatology Associates, Louisville, KY, 4Community Health Network, Noblesville, IN, 5PopMed Solutions, Boyds, MD

Meeting: ACR Convergence 2021

Keywords: Access to care, outcomes, Population medicine, rheumatoid arthritis, treat to target

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The RAPP quality improvement project is a voluntary consortium of practicing rheumatologists founded in 2013 by Timothy Harrington MD, MACR. The primary focus is to provide accurate, on-time disease activity assessments and necessary treatments for an entire RA population consistent with T2T recommendations. We identified a bottleneck at available physician appointments as a major impediment. To address this bottleneck, RAPP practices utilized principles of chronic disease management (POPMED) such as team care with advanced practice providers and medical assistants gathering pertinent clinical, lab and imaging data 1-2 weeks prior to the actual clinical visit with the Rheumatologist. We now report our experience with RA disease activity outcomes, timeliness of care and Rheumatologist productivity over 6 years in 4 RAPP practices that have implemented both T2T care and POPMED principles.

Methods: The 4 Rheumatology practices included in this analysis represent a spectrum of community-based, physician-owned Rheumatology providers including two large ( >250 MDs) multispecialty groups, a 4 Rheumatologist practice and a solo practice. Timeliness of care was judged by fulfilling ACR/EULAR guidelines of assessments every 3 months for high or moderate disease activity (HDA) patients and 3-6 months for low or controlled disease activity (LDA) patients. RAPP practices also chose to use one or more composite disease activity profile from a panel (Rapid-3, CDAI, SJC, TJC, MD Global) . All or part of these were obtained by team members at each visit prior to the Rheumatologist seeing the patient. Only MBDA (Vectra) testing was utilized in all 4 practices at prescribed intervals.

Results: Over 6 years the 4 practices in total decreased the number of Rheumatologists from 11 to 10 while increasing the number of team members from 54 to 76. The added positions included 8 NP/PAs, 4 MAs and an assortment of other support staff. Total annual new patient visits increased 54% from 4165 to 6424(Image1).There was a 66% increase in the RA patient panel from 2673 (range 428 to 824) to 4428 (690-1307). MBDA scores demonstrated that initially 35% of RA patients had HDA and 42% were evaluated on time (Image 2). 6 years later only 16% of RA patients had HDA with 56% evaluated on time. A concomitant increase in RA patients with LDA from 24 to 46% was noted with on time evaluations increasing from 55% to 68%.

Conclusion: Creation of patient care teams and re-designing the patient visit into two components allowed almost 1800 additional patients with RA to access Rheumatology care despite an actual decrease in the number of Rheumatologists in the 4 practices. Associated with improved access, the number of RA patients with HDA declined dramatically (35% to 16%) and LDA increased (24 to 46%) as the timeliness of their visits improved. We conclude that Dr Harrington’s vision of using T2T care and POPMED principles to improve quality and access to care for patients with RA has proven true.

Finally, the dramatic improvements in Rheumatologist productivity associated with implementing team care suggests the RAPP project can be a model to mitigate the shortage of Rheumatologists both now and projected in the future.

RA Panel and New Patients.jpeg”

RA Disease Activity Distribution by MDMA.jpeg”


Disclosures: W. Arnold, Setpoint medical, 2; E. Arnold, Myriad, 6, SetPoint, 2; D. Sikes, Myriad, 2, Abbvie, 6; G. Crump, Myriad, 1, 6, AbbVie, 2, 6, Novartis, 1, 2, 6, UCB, 2, 6, Horizon, 1, 6, Amgen, 6, Exagen, 1; K. Thomas, None; a. johnson, None.

To cite this abstract in AMA style:

Arnold W, Arnold E, Sikes D, Crump G, Thomas K, johnson a. Rheumatoid Arthritis Practice Performance (RAPP) Project at 6 Years: Population Medicine (POPMED) Principles and Treat to Target (T2T) Care Yield Dramatic Improvements in Both Outcomes and Access for RA Patients and Productivity for Rheumatologists [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-practice-performance-rapp-project-at-6-years-population-medicine-popmed-principles-and-treat-to-target-t2t-care-yield-dramatic-improvements-in-both-outcomes-and-access-for/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-practice-performance-rapp-project-at-6-years-population-medicine-popmed-principles-and-treat-to-target-t2t-care-yield-dramatic-improvements-in-both-outcomes-and-access-for/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology